Dengue virus sustains viability of infected cells by counteracting apoptosis-mediated DNA breakage

Himadri Nath[1], Keya Basu[2], Abhishek De[3] and Subhajit Biswas[1,*]

[1] Infectious Diseases & Immunology Division, CSIR-Indian Institute of Chemical Biology (IICB), 4, Raja S.C. Mallick Rd, Jadavpur, Kolkata-700032, West Bengal, India;

[2] Department of Pathology, Institute of Post-Graduate Medical Education and Research (IPGMER) and Seth Sukhlal Karnani Memorial (SSKM) Hospital, 244, Acharya Jagadish Chandra Bose Rd, Bhowanipore, Kolkata-700020, West Bengal, India;

[3] Department of Dermatology, Calcutta National Medical College & Hospital, Kolkata-700014, West Bengal, India.

*Correspondence: subhajit.biswas@iicb.res.in

Short title: Dengue virus sustains viability of infected cells by counteracting apoptosis

Abstract

Dengue is the most important arboviral disease inflicting mankind. This mosquito-borne Flavivirus causes mild to severe dengue fever which in some cases leads to life-threatening conditions namely, dengue haemorrhagic fever and dengue shock syndrome. Annual infection is estimated at 390 million globally with 96 million manifesting clinically. So, ≥80% infections are asymptomatic and self-limiting. Dengue virus (DV) non-structural protein 1 (NS1) is a proven virotoxin abundantly present in the victim's blood. We found that DV-infected or only NS1-expressing cells both can induce Cleaved Caspase3, due to antiviral response of host cells. NS1-transfected cells also showed nuclear damage and significant levels of DNA breaks suggestive of ensuing apoptosis. So, it was established that NS1 alone is capable of causing apoptosis. Surprisingly, despite secreting similar amount of soluble NS1, the DV-infected cells showed intact nuclear morphology and background levels of DNA nicks. These observations suggested that DV downregulates apoptosis of infected cells, which is a viral strategy against host defence. Furthermore, DV-infected cells counteracted Camptothecin-induced apoptotic DNA break. DV-infection was also found to keep the infected cells metabolically more active than only NS1 expressing cells. So, DV bypasses cellular defence against virus i.e. apoptosis by counteracting cellular DNA break and keeps the infected cells metabolically active to support virus replication for longer period which eventually results in high virus titer in circulation. Our findings reveal another level of intricacy involving dengue virus-host interactions and perhaps explain why ≥80% DV infections are asymptomatic/self-limiting despite the presence of NS1 virotoxin in infected cells.

Author Summary

NS1, a virotoxin, abundantly present in Dengue patients blood, is a major player behind disease patho-biogenesis including plasma leakage. Despite the presence of NS1 in blood, Dengue is asymptomatic and self-limiting in more than 80% dengue virus (DV) infected people. We investigated this observation and found that plasmid-mediated NS1 expression and secretion in cells are sufficient to cause programmed cell death (apoptosis) and associated cellular DNA breakage. However, cells infected with dengue virus and secreting equivalent amounts of NS1 didn't exhibit apoptotic DNA breakage. Consequently, DV-infected cells showed better survival than cells in which only NS1 was transiently expressed by transfection with expression plasmid. We also found that DV can even prevent chemical-induced apoptotic DNA damage in infected host cells. So, DV bypasses host antiviral defence i.e. apoptosis by counteracting cellular DNA breakages and keeps the infected cells metabolically active to prolong virus replication.

Introduction

Dengue is the most serious life-threatening vector-borne viral disease plaguing mankind. It affects approximately 390 million (95% Credible interval: 284-528) people annually across the globe of which 96 million (CI: 67-136) manifests clinically. So, there is a huge population where Dengue virus (DV) infection is asymptomatic. Dengue is endemic to more than 100 countries which makes one-third of the world's population to live in risk areas, which are tropical and subtropical regions (1). Dengue virus is a member of the family *Flaviviridae*, genus Flavivirus, and is transmitted to humans by the bite of female *Aedes* mosquitoes. The infection with any of the main four DV serotypes (1-4) can either be asymptomatic or manifest in three clinical forms of increasing severity: dengue fever (DF), dengue haemorrhagic fever (DHF), and dengue shock syndrome (DSS). Dengue fever is characterized by fever, headache, muscle and joint pain and rash. Dengue haemorrhagic fever (DHF) is characterized by thrombocytopenia, increase in vascular permeability and plasma leakage. In severe cases, circulatory failure and shock (DSS) and even death may occur (2). Dengue virus particle is approximately 500Å in diameter. It has a positive sense RNA genome of ~10.7 Kb coding for three structural and seven non-structural proteins. Capsid, precursor-Membrane & Envelope are three structural proteins. Non-structural proteins are NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5 (3).

DV NS1 (48 KDa) is secreted from infected mammalian cells as hexamer and widely used as diagnostic marker (4). NS1 is essential for virus replication (5,6) and the secreted form contributes to complement fixation (7) and pathogenesis. NS1 has been shown to act as PAMP and activate TLR4, leading to induction and release of pro-inflammatory cytokines and chemokines (8). Antibodies against DV NS1 are responsible for endothelial cell apoptosis (9,10). Based upon *in vitro* data or mouse models, it was suggested that endothelial

cell apoptosis led to vascular permeability during DV infections. The latter was caused by

direct infection of endothelial cells by DV or damage by antibodies against NS1, which can

cross-react with endothelial cells (10–13). However, plasma leakage improves within 1 to 2

days in DHF/DSS patients who receive appropriate fluid resuscitation, and tissue samples

from these patients showed little structural damage in their blood vessels (14–17). Therefore,

apoptosis of endothelial cells induced by DV infection or anti-NS1 antibodies is not sufficient

to support the clinical outcome. Recent evidences show that DV NS1 can directly modulate

endothelial cell permeability which leads to vascular leakage (18). So, endothelial

dysfunction but not apoptosis induced by dengue-specific factor(s) is currently considered to

play a more important role in causing vascular leakage in DHF/DSS (14,17). Circulating

levels of sNS1 vary from 0.04-0.6 µg/mL for DF, 0.6-2.5 µg/ml with reports of up to 15

µg/mL in case of DHF and persist for up to 4-6 days from the onset of fever (19). These data

are based on NS1 levels measured in the bloodstream of infected patients. However, NS1

may exit the bloodstream into tissues, leading to an apparent clearance of NS1 from the blood

and increased presence in tissues (20). Circulating NS1 levels in DF and DHF positively

correlated with disease severity (19). It is, indeed, intriguing that although NS1 is highly

pathogenic and considered a virotoxin, only few DV infected individuals develop severe

illness while majority of the cases are asymptomatic or self-limiting (21).

From the above findings, the direct effect of NS1 production in infected cells on cellular

apoptosis is not very clear. This has led us to revisit the patho-biogenesis of NS1 in case of

recently circulating DV clinical isolates, in liver and kidney cell lines. In this study we

estimated soluble NS1 (sNS1) in cell lines infected with known copy numbers of DV clinical

strains. Based on the sNS1 levels, we transfected NS1 gene constructs in order to express

comparable amounts of sNS1 in same cell lines to observe the effect of equivalent amounts of

NS1 on cells, in presence and absence of DV infection.

We found that DV infection or NS1 expression, either condition, induces apoptosis in both

cell lines. But DV infection exerts control/check over late apoptotic DNA break which kept

the cells alive and capable of more virus replication. Thus, we have discovered this DV-

mediated protection of host cellular DNA from apoptosis-induced breakage. We believe that

this is a strategy, DV deploys to delay cell death, thus allowing more time and space for virus

replication within the infected cells. Our observation also provides a plausible explanation for

the high cell free DNA that has been observed clinically in DV infections (22).

Results

Dengue virus and NS1 only, both can induce Cleaved Caspase3 (CC3)

Secreted NS1 from DV1-HNSB-P4-infected (10 virus copies or genome Equivalents (gE)

/cell) and NS1-plasmid-transfected Huh7 cells in six well plates (approx. 10^6 cells at

confluence), were measured in multiple experiments (Supplementary Table1). It was

estimated that 1.0 µg pcDNA3.1-NS1 expression construct results in expression of 2.55 (±

0.59) µg/ml DV1-NS1 in the cell supernatant in 96h post-transfection, equivalent to the

amount which is 2.53 (± 0.79) µg/ml expressed at 96h post-infection when the same number

of cells were infected with the aforesaid virus inoculum (10 virus copies/cell).

Two more NS1-plasmid quantities i.e. 3.3 µg and 0.5 µg were tested, expressing 4.36 (±

0.33) and 0.36(±0.04) µg/ml NS1 respectively under similar conditions. It was observed that

DV1-infected cells expressed more CC3 than NS1-transfected cells. The 3.3 µg NS1-

plasmid-transfected cells were closer to virus-infected cells, in terms of inducing CC3

followed by 1.0 µg and 0.5 µg plasmid transfected cells (Fig. 1a-1b). So, NS1 alone can

induce apoptosis as observed from increased expression of CC3 over cell control in

transfection experiments. Positive correlation between NS1 expression levels and CC3 in

transfected cells, confirmed the above proposition.

Furthermore, CC3 levels from 1.0 µg NS1-plasmid-transfected cells were less than that of

virus infected cells (Fig. 1b), both expressing equivalent levels of sNS1 (2-3 µg/ml). DV1-

HNSB-P4 infected Vero cells expressed less NS1 compared to Huh7, 0.4 (± 0.09) µg/ml at

62h post infection. Still such cells also showed higher CC3 levels compared to uninfected

cells (Fig. 1c-1d).

Now, CC3 expression is considered a hallmark of apoptosis progression, so such cells were

supposed to undergo apoptotic DNA break. TUNEL assay was performed to confirm this.

Dengue virus shows control over apoptotic DNA breaks in DV infected cells

DV1 NS1 plasmid transfected Huh7 cells showed high percentage of TUNEL positivity,

29.17 (± 2.48) % for 1.0 µg plasmid and 36.67(±2.26) % for 3.3 µg plasmid. Increase in

percentage of DNA nicks was positively linked to increasing plasmid transfection,

confirming apoptosis induction by NS1. Surprisingly, DV1-HNSB-P4 infected cells,

expressing similar concentration of sNS1 2.53 (± 0.79) µg/ml like 1.0 µg NS1-plasmid

transfected cells (2.55 (± 0.59) µg/ml), showed insignificant levels of apoptotic DNA nicks

0.97 (± 0.32) %. In fact, the infected cells behaved very similar to untreated cell and mock

transfection controls, 2.1 (± 0.40) and 1.5 ± (0.8) % respectively (Fig. 2a-2b). So, DV1-

HNSB-P4 infected liver cells expressed more CC3 (Fig. 1a-1b) compared to NS1-transfected

cells but no subsequent DNA breakage was observed even up to 96h post-infection (Fig. 2a-

2b). This observation suggests that DV counteracts NS1 mediated-apoptosis of infected cells,

as evident from the absence of DNA breaks.

Similar study was also conducted repeatedly in Vero cells. Again, there were more apoptotic

DNA nicks in case of NS1 transfected Vero cells, confirming that only NS1 expression in

cells was enough to induce apoptosis. DV1-HNSB-P4-infected Vero cells showed minimum

TUNEL positivity (Fig. 2c-2d) as observed in case of Huh7 cells.

The aforesaid phenomenon was found true for both DV2 and DV3. In case of DV2 clinical

strain, DV2-HNSB-NS1-transfected cells showed more apoptotic DNA breaks than only

virus infected cells (10 virus copies/cell). 3.3µg DV2-NS1 plasmid transfected cells were

more TUNEL positive (48.77 ± 2.55 %) than infected cells (7.83 ± 1.07 %) (Fig. 2e-2f).

Interestingly, this was observed with even higher levels of sNS1 production by DV2 infected

(2.71 ± 0.08 µg/ml) than NS1-transfected cells (1.94 ± 0.11 µg/ml) (Supplementary Table1).

So, despite higher level of NS1 expression in infected cells, apoptotic DNA break was lower

compared to DV2-NS1 transfected cells. In case of DV3, the concentration of sNS1 in

transfected cell supernatant was 1.56 (± 0.16) µg/ml in case of 3.3 µg DV3-HNSB-NS1

plasmid transfection. DV3-HNSB-P4 infected cells secreted 1.21 (± 0.15) µg/ml sNS1

(Supplementary Table1). Again, for DV3, NS1 expression in transfected cells resulted in

41.87 (± 2.32) % apoptotic DNA break, whereas DV3 infected cells expressing equivalent

concentration of sNS1 showed only 6.77 (± 1.55) % TUNEL positive (apoptotic) cells (Fig.

2e-2f).

Dengue virus exerts inhibitory effect over induced apoptotic DNA break

Ladder assay was performed on repeated occasions with Camptothecin (4.0 µM) treated-Vero

cells as positive control. In this experiment, DV1-HNSB-P4 infected cells were also treated

with Camptothecin (4.0 µM) to promote apoptotic DNA break. Camptothecin treated cells

showed distinct ladder pattern resulting from DNA fragmentation which occurs at late

apoptosis (Fig. 3a). Again, DV1-HNSB-P4 infected cells did not show apoptotic DNA ladder

pattern even at 62h post-infection (point of cell harvesting), supporting the TUNEL assay

results. Replication of virus was confirmed by 5-fold increase in sNS1 in supernatant over

inoculum (Supplementary Table1).

DV1-HNSB-P4 infected cells together with Camptothecin (4.0 µM) treatment produced

relatively reduced ladder pattern in comparison to only Camptothecin treated cells (Fig. 3 a-

b). So, this competitive assay showed that Dengue virus is actually opposing classical

apoptosis (by Camptothecin) and therefore, protecting the cellular DNA from fragmentation.

This data conclusively proved that DV prevents cellular DNA breakage which is considered a

salient feature of late apoptosis. Furthermore, it is observed that DV protects cellular DNA

from damage even in presence of Camptothecin i.e. under high levels of CC3, as previously

documented (Fig. 1c-1d).

DAPI staining revealed that nuclear morphology of DV1 infected Huh7 cells was quite intact

and similar to that of uninfected cells. In contrast, 1.0 µg DV1 NS1 plasmid transfected cells

showed signs of nuclear damage in comparison to mock transfected (Fugene only) cells (Fig.

3c). We have already demonstrated that 1.0 µg DV1 NS1 plasmid transfected and DV1

infected (10 virus copies/cell) cells secrete comparable amounts of sNS1. It is therefore,

expected that there should be similar levels of damage of nuclear morphology for both

conditions. But nuclear morphology of DV1-infected cells was just like that of untreated

cells, again providing direct visual evidence of Dengue virus's control/check over apoptotic

DNA damage and cytotoxic effects of NS1.

Dengue virus keeps the infected host cell metabolically active reducing sNS1-mediated cytotoxicity

Metabolic activity of DV infected Huh7 cells (DV1, 2, 3) and their respective NS1 transfected cells were tested using MTT assay. Cells infected with DV at 10 virus copies/cell showed 89% viability in case of DV1; 86% with DV2 and 80% with the DV3 clinical strain at 48h post-infection. Parallel sets of cells were transfected with respective NS1 constructs in amounts estimated to secrete equivalent amount of sNS1. It was observed that cell viability at 48h post-transfection was lower by 10-20% compared to DV infected cells, supporting the previously observed protective role of virus infection over NS1 cytotoxicity (Table 1).

% of viable cells in infected cells (10 virus/cell)	R1	R2	R3	R4	Mean (SD)
DV1	73.57	110.08	80.79	91.34	88.95 (15.87)
DV2	90.94	90.55	81.77	82.35	86.40 (5.02)
DV3	89.97	67.71	87.23	73.37	79.57 (10.74)
% of viable cells in NS1 plasmid (0.11μg) transfected cells	R1	R2	R3	R4	Mean (SD)
DV1-NS1	67.11	62.44	73.33	57.76	65.16 (6.65)
DV2-NS1	63.65	72.30	84.49	72.64	73.27 (8.56)
DV3-NS1	69.87	70.91	67.63	76.71	71.28 (3.87)

Table1: Percentage cell viability or metabolic activity as observed in MTT assay.

Metabolic activities of infected cells were compared with uninfected controls. For NS1 transfected cells, metabolic activity was compared with mock Fugene HD transfected cells. For each type of treatment, there were four replicates, denoted as R1, R2, R3 and R4.

Evidences in support of viral replication and budding of mature virions during cell culture experiments

Secreted NS1 levels in experiments were measured using quantitative NS1 ELISA as described in methods. Individual ELISA, with standards, was performed for each experiment. In case of infection with DV1-HNSB-P4, DV2-HNSB-P4 and DV3-HNSB-P4, increase in sNS1 was expressed in microgram and as fold-increase over inoculum- sNS1 level (Supplementary Table 1). Increase in sNS1 level was one evidence of successful viral replication and NS1 production during every experiment. Interestingly, Camptothecin treatment did not have any significant effect on sNS1 production for virus-infected cells (Supplementary Table1).

Under same experimental conditions, Huh7 cells in six well plates were infected with above said three DV serotypes at 10 virus copies/cell. Inoculum was removed after virus adsorption and cell monolayer was washed with 1XPBS three times as done in case of all infections. Infected cells were harvested at 96h post infection and RNA was extracted. RNA from infected cell supernatant was also extracted to find the DV titer in it. Virus copy number was determined in cells and supernatant, using one step qRT-PCR(SYBR) and specific band size was confirmed in gel electrophoresis.

The means of intracellular virus copies were $4X10^7$ ($\pm1.6X10^7$), $6X10^6$ ($\pm7X10^4$) and $2X10^7$ ($\pm10^6$) for DV1, DV2 and DV3 respectively. Similarly, supernatants of those infected cells also showed high virus titers, suggesting successful virus replication and budding of mature virions. Mean total virus titers in DV1, DV2 and DV3 infected cell supernatants (3ml) were $4X10^7$ ($\pm2X10^7$), $7X10^6$ ($\pm5X10^6$) and $3.5X10^7$ ($\pm10^7$) respectively. So, infected cells were secreting equal or more virus than intracellular titers (Table 2).

To further confirm virus replication, immunofluorescence of DV infected Huh7 cells was

done using anti-DV envelope primary Ab (DE1, Abcam) and goat anti-mouse IgG (Alexa

fluor 488) secondary Ab. The presence of high virus titer was supported by viral envelope

staining in more than 70% Huh7 cells. Nuclei of heavily infected cells were quite intact,

again supporting DV-induced cell survival for increased virus replication (Fig. 4), opposing

the deleterious effects of NS1 production and secretion. Primary Ab was developed based on

envelope glycoprotein sequence of DV2 (Strain-16680) and worked best for DV2 staining,

then DV1 but was found not effective for DV3 staining.

	Intracellular virus copies Mean (±SD)	Virus copies in total supernatant (3ml) Mean (±SD)	Total yield of virus copies Mean (±SD)
DV1	4×10^7 ($\pm 1.6 \times 10^7$)	4×10^7 ($\pm 2 \times 10^7$)	8×10^7 ($\pm 4 \times 10^7$)
DV2	6×10^6 ($\pm 7 \times 10^4$)	7×10^6 ($\pm 5 \times 10^6$)	1.3×10^7 ($\pm 5 \times 10^6$)
DV3	2×10^7 ($\pm 10^6$)	3.5×10^7 ($\pm 10^7$)	5.5×10^7 ($\pm 10^7$)

243   **Table2: Virus copy number by qRT-PCR of RNA, extracted from infected Huh7 cells**
244   **and supernatants.**

Discussion

We have ascertained that dengue virus-infected cells (Vero and Huh7) and only NS1 gene-transfected cells, expressing equivalent amounts of sNS1 in the culture supernatant, both can induce cleaved caspase 3 (CC3). CC3 is a definitive marker of late apoptosis events that include subsequent fragmentation of cellular DNA. Our data suggest that virus-infected cells induce more CC3 than observed in case of only NS1-transfected cells (Fig. 1a-1b). So apparently, NS1 contributes to one major part of the apoptotic potential of DV-infected cells, the other part possibly comes from other pro-apoptotic factors like Capsid, Membrane, Envelope, NS2A and NS2B (23). 3.3 µg DV1 NS1 plasmid transfected cells expressed highest amount of CC3, although less than virus infected cells (Fig. 1b). 1.0 µg and 0.5 µg plasmid transfected cells expressed reduced CC3. This suggests positive correlation of NS1 in cells and CC3 expression. The TUNEL assay and ladder assay results further confirmed that NS1 alone is capable of inducing apoptosis, resulting in DNA nicks, producing positive TUNEL signals (Fig. 2), damage of nuclear morphology (Fig. 3c) and cellular DNA fragmentation which was evident from ladder assays (Fig. 3a).

In conclusion, our studies produced direct evidence, for the first time, that NS1 alone is capable of inducing apoptosis in cells (Huh7, Vero) at levels comparable to those found in real life DV clinical cases (19).

It had been previously reported that DV infection in mouse neuroblastoma cell line, initiated survival signal via activation of PI3K and Akt phosphorylation. This survival signal was shown to prevent DV induced CC3 expression up to 24h (24). However, it is evident from our findings that DV infection actually results in CC3 expression, detectable even at 96h post infection. Possibly, PI3-AKt activation-mediated survival signal appears to be transient

lasting for only 24h post infection. It is apparent, that as DV infection progresses, CC3 is

expressed to induce apoptosis plausibly to eliminate virus infected cells.

This obviously raised the question whether DV-infected cells really undergo apoptosis as part

of host defence against viral infection? Surprisingly, we discovered that although DV

infection induces the apoptosis mechanism of host defence in infected cells, cellular DNA is

someway protected from apoptotic damage and fragmentation (Fig. 2-3). Between 1.0 μg

plasmid transfection and virus infection, DV1 infected cells expressed more CC3 than

transfected cells. So, apoptotic DNA break as measured by TUNEL assay was supposed to be

more in infected cells than in 1.0 μg plasmid transfected cells. But it was found that virus-

infected cells harboured much less apoptotic DNA break than transfected ones, in case of DV

1, 2 and 3 (Fig. 2a-2f). This was further confirmed by the fact that DV infected cells, despite

Camptothecin treatment, repeatedly showed reduced laddering pattern compared to only

Camptothecin treated cells (Fig. 3a-b). Camptothecin is known to induce classical apoptosis

and DNA fragmentation. It was therefore, apparent from our observations that DV infection

counteracts apoptosis-mediated DNA breakage, even up to 96h post-infection. These points

towards some different ability of DV, to prolong the effects of cellular apoptosis other than

only early stage host survival signal via PI3K-Akt pathway activation. The results of the

MTT assays revealed that dengue virus also keeps the host cell metabolically active

counterbalancing host antiviral response i.e. apoptosis. On the other hand, NS1 expression

and secretion from cells in absence of whole virus led to substantial metabolic damage or

mortality of cells (Table 1).

Our observations perhaps explain why majority (≥80%) of DV infections in humans are

asymptomatic/self-limiting (21) despite the fact that sNS1 on its own is a virotoxin capable of

causing cytotoxicity/apoptosis. The results also prove that sNS1-mediated cytopathic effects

are suppressed/ameliorated in case of virus-infected cells. These observations encourage us to

propose that DV disease outcome/severity may depend on the "tilt" of the balance between

DV infection-mediated prolongation of cell viability (by check of cellular apoptosis and

resulting DNA damage) and induction of apoptosis by proapoptotic virus proteins like NS1.

In this context, it is interesting to note that symptomatic to severe DV cases have been

implicated in case of the following conditions/pre-disposing factors, namely (I) Antibody

dependent enhancement (ADE) in case of secondary infection (25); (II) Level of sNS1 and

viraemia (19,26); case fatality was high when NS1 antigenaemia was high as observed in

case of DV2 infections. In contrast, higher case fatality was linked to higher viraemia in case

of DV3 infections (19,26); (III) Co-infection with different serotypes (27); (IV) Immune

status of the host. It appears that the above factors decide the fate of DV infection affecting

the aforesaid "tilt" of the balance between asymptomatic condition (self-limited recovery)

and disease progression.

Our studies involved three clinical strains of Dengue virus, representing serotype 1, 2 and 3,

circulating in Kolkata during 2017. It has been observed that clinical strains of DV are not

plaque-forming at early passages in cell(28). The same appears to hold true for our clinical

strains. DV strains with low passage number (passage 4 for all three) were used in all assays

in order to maintain them closer to the wild-type circulating strains and to mimic the clinical

scenario as much as possible. Virus replication in Huh7 and Vero cells was confirmed in

infected cells. Alongside high intracellular virus titer, infected cells also secreted equivalent

or more mature virions, suggestive of successful virus infection of cells resulting in high

viraemia. Mature virions were released by budding keeping the cells intact as evident from

high virus copy numbers in infected cell supernatants (Table 2). Additionally, DV replication

in individual experiments was confirmed by fold increase in sNS1 level in supernatants

(Supplementary Table1). Enveloped DV in infected cells was also visualized by

immunofluorescence using Ab against DV envelope glycoprotein (Fig. 4). About 70% DV

infected cells showed fluorescence in case of both DV1 and DV2 infection confirming

similar level of virus infection for the experiments at least for DV1 and DV2. The

commercially available envelope antibody (originally developed as anti-DV2) was not

effective in staining DV3 (data not shown). The nuclei of DV-infected cells were similar to

those of the uninfected cells and were in sharp contrast to the damaged nuclei in case of NS1-

transfected cells. This observation again emphasized DV mediated survival of infected host

cells in the presence of NS1 virotoxin in the background.

It is still not clear to us how DV exactly protects infected cells' DNA. Capsid and NS5 are

viral proteins known to migrate to the nucleus, so they may have a role in this (29–31). The

explanation appears to be not straightforward and warrants further in-depth investigation-it

may be due one or more viral factors or modulated host factors or a combination of both. It is

has been previously reported that Ab against NS1 can induce apoptosis in endothelial cells

(9). However, as mentioned before plasma leakage gradually ceases within 1 to 2 days in

DHF/DSS patients who receives appropriate fluid therapy. Tissue samples from these patients

showed almost no structural damage in their vessels(14–17). Therefore, apoptosis of

endothelial cells induced by DV infection or anti-NS1 antibodies is not sufficient to explain

the clinical outcome. Our findings support this observation because DV-infected cells were

prevented from undergoing DNA fragmentation and subsequent cellular blebbing and

shrinkage even at 96h post-infection. Currently, plasma leakage is best explained by the fact

that NS1 has been shown to be capable of disrupting vascular cell membrane glycocalyx and

alter endothelial permeability(18,32).

Our finding also corroborates well with the fact that Dengue virus infection is associated with

increased cell free DNA (cfDNA) in plasma. There are several reports that cfDNA increases

in DV infected patients and is associated with disease severity(22). In this article the authors

have said cellular apoptosis to be the source of this high cfDNA, but the mechanism was not

clear; as apoptosis was supposed to produce fragmented DNA, to be removed soon via

salvage pathways and excretion. But if DV infection protects cellular DNA from apoptotic

break, that will result in large DNA fragments which may stay in plasma for longer period.

Our results possibly explain this cfDNA in Dengue infections more rationally. Disease

severity is positively linked to DV titres; more virus replication means infection of more cells

of the body; more cells rupture to release progeny virions and "protected" cfDNA-this

perhaps explains why more cfDNA in plasma has been recorded as a biomarker of DV

disease severity(33).

DV infection of cells definitely induces apoptosis as a response of host defence(24). Adding

to this, we have shown NS1 alone is capable of inducing apoptosis, besides other well-known

pro-apoptotic factors like virus capsid protein. So, it is a viral strategy against host defence

that DV infection "protects" cellular DNA from apoptosis-induced fragmentation, to keep the

host cell metabolically active even with toxic NS1 expression as observed. This would allow

the virus a window to replicate for a relatively longer period using the host cellular

machinery (we recorded up to 96h post-infection) followed by budding of mature virions

(Table 2). This strategy is advantageous from the point of DV infection biology. In a nutshell,

virus-mediated "protection" of cellular DNA allows more time and space for virus replication

within infected cells, in the face of ensuing apoptosis, thereby allowing the virus to reach

higher titres to establish successful viraemia in the host. Successful virus transmission and

propagation in an endemic region occurs when the virus is present in high titres in circulation

so that the mosquito vectors during blood meal could take in adequate number of infectious

virus particles, thereby ensuring effective virus transmission and persistence in the host and

vector populations.

Materials & methods

Cell Lines

Vero and Huh7 cells were obtained from NCCS, India. Cells were cultured in DMEM
(D5796, Sigma) supplemented with 10% FBS (Gibco) and Pen-Strep and L-Glutamine mix
(Sigma). Monolayers of cells during experiments were maintained using DMEM
supplemented with 1% FBS. Cells were grown at 37^0C with 5%CO_2. During passage, cells
were washed with PBS (1X) & detached with Trypsin-EDTA (1X) (Gibco). For culture,
Thermo-Nunc flasks and culture plates were used. C6/36 cells were cultured in MEM
(Sigma), supplemented with 10% FBS (Gibco), Pen-Strep and L-Glutamine (Sigma) and
Fungizone (Gibco). C6/36 cells were grown at 28^0C with 5%CO_2.

Viruses

Serum samples from Dengue fever patients were collected and supplied by Dr. Keya Basu
and Dr. Abhishek De with proper information and prior written patient consent. This study
was approved by the Ethics Committee on Human Research of CSIR-Indian Institute of
Chemical Biology, Kolkata. All serum samples were confirmed as Dengue virus-positive by
means of NS1 diagnostic ELISA test (Platelia, Biorad). Serum samples were filtered using
Millipore 22µM PES syringe filters. 70% confluent monolayer C6/36 cells were infected with
filtered serum (Inoculum volume made up to 800µl in MEM for T-25 flask of C6/36 cells);
adsorption was done for 2h under normal cell culture conditions with intermittent shaking at
every 15 mins. Cells with virus were incubated for 120h. Three such passages were given in
C6/36. During harvesting T-25 containing cells were scraped in 1ml supernatant. These cells
in supernatant were freeze-thawed and centrifuged at 13,000 rpm for 15min at 4^0C to pellet
the cellular debris. The resultant clear supernatant was aliquoted and stored at -80^0C as virus
stocks. Virus serotyping was done as described by Lanciotti et al(34). Virus titer was

determined using SYBR-based one step qRT-PCR with Luna Universal One Step qRT-PCR

reagent (NEB). Quantstudio 5 (AB) was used to run the qPCRs. Primers as described by

Lanciotti were used in qRT-PCRs.

TUNEL assay

TUNEL assay was done as per protocol of APO-BrdU™ TUNEL Assay Kit with Alexa

Fluor™ 488 Anti-BrdU (Thermo, Life Tech). Adherent cells were trypsinized and pelleted

along with floating cells. The pellet was resuspended in 600µl 1X PBS. Then 4.4 ml of 70%

chilled ethanol was added, keeping the cells suspended by mild vortexing. Cells in 70%

ethanol were stored at -20^0C overnight. Next day, cells were centrifuged at 300g at 4^0C for

5mins and the supernatant was decanted. Cells were then washed twice with 1ml wash buffer.

Thereafter, the pelleted cells were suspended in 50 µl reaction mix and incubated at 37^0C for

70mins. During incubation, tubes were tapped at every 15mins interval to keep the cells in

suspension. After incubation cells were rinsed twice with 1ml of rinse buffer. Then 100 µl of

Antibody mix (5ul in 145ul Rinse Buffer) was added to each tube, keeping the cells

suspended by tapping. Cells with antibody were incubated at room temperature (~25^0C) for

30 mins. The cells were then washed once with 700 µl rinse buffer. After that, cells were

suspended in 500 µl Propidium iodide (PI)-RNaseA solution and transferred to FACS tube.

Cells were allowed to incubate with PI for 30mins, followed by FACS analysis in BD

LSRFortessa. Analysis of data was done using the BD FACSDiva 8.0.2 software. In TUNEL

data analysis, gating for virus infected cells was based on uninfected cell control. In case of

transfection experiments, gating was based on mock transfection control.

Apoptotic DNA Ladder assay

Adherent cells in T-25 flasks were detached using trypsin-EDTA and pelleted by

centrifugation. Pelleted cells were lysed using cell lysis buffer (1X PBS, 0.2% TritonX100).

RNaseA (Invitrogen) was added (2 µl) to the cell lysate (about 200-300 µl) and the resultant

mix was incubated at RT for 5mins. This was followed by addition of 20 µl Proteinase K and

incubation at 56^0C in heat block for 2h. Then equal volume of Phenol-Chloroform-Isoamyl

alcohol (25:24:1) (HiMedia) was added and mixed by inverting. This was followed by

centrifugation at 13,000rpm for 15mins. Of the three layers visible, upper most transparent

layer was aspirated carefully to a new 1.5 ml Eppendorf tube. Isopropanol (1.2 times the

volume of aspirated supernatant) was added to the supernatant and mixed well by inverting. 1

µl of Glycogen (Invitrogen) was added to the tube before storing it at -20^0C for 2hr. The tube

was then centrifuged at 13,000rpm for 15mins at 4^0C to obtain the DNA pellet. Supernatant

was discarded and pellet was washed using 70% ethanol twice. Pellet was air dried and

suspended in 40ul nuclease-free (NF) water (Ambion). DNA quantity and quality were

ascertained using Nanodrop One (Thermo). Equal quantities of cellular DNA from different

conditions of the experiments were subjected to gel electrophoresis in 1.4% agarose gel with

SYBR safe dye (Invitrogen). AGEP was done at 50V (5V/cm) for 3hr. Gel was observed in

Gel Logic (Carestream) under UV transillumination.

NS1 ELISA

ELISA was done as per protocol of Bio-Rad Platelia Dengue NS1 ELISA. In case of

quantitative ELISA, serial dilutions of recombinant NS1 Antigen (Ag) (Bio-Rad) was used.

Dilutions of Ag were made in PBS (1X). ELISA reading was taken in iMark plate reader**.**

Standard curve was prepared from ODs of known dilutions of NS1-Ag. From the equation of

that curve soluble NS1 quantity of unknown samples were determined. Separate ELISAs

were performed for each experiment.

Western Blot experiments to detect Cleaved Caspase3

Monolayer of Vero or Huh7 cells was subjected to Camptothecin (4uM) treatment for 12-13h

or NS1 transfection or dengue virus infection. Lysis buffer (1% TritonX100 in PBS, 10U/ml

DNase1-Cat. No. D2821, Sigma with Proteinase inhibitor (Pierce, Thermo)) was directly

applied on adherent cells and kept on ice for 10mins. Lysate was aspirated into 1.5ml tube

and centrifuged at 13,000rpm for 15mins at 4^0C. Clear supernatant was aspirated and used for

Western blotting. Protein quantification was done using BCA assay kit (Pierce). Cell Lysate

was separated by means of 5% (Stacking) and 15% (Resolving) SDS PAGE gel

electrophoresis, using running buffer (25mM Tris, 192mM Glycine, 0.1% SDS: pH 8.3) at

constant voltage of 90V for 2.5h. To observe the relative position of protein in gel, two

protein ladders, namely PageRuler (Thermo) & Precision Dual Colour ladder (Bio-Rad) were

used. For subsequent analysis proteins were transferred onto Nitrocellulose membrane using

Trans-Blot Turbo Transfer System (Bio-Rad). Membrane was blocked using TBST with 5%

skimmed milk for two hours at room temperature. Primary anti GAPDPH Ab, HRP conjugate

(1:2000) was used as housekeeping protein control. Strips of membranes corresponding to

target proteins (CC3 or GAPDPH) were incubated with Primary anti Cleaved Caspase3 rabbit

Ab (1:1000) or anti GAPDPH Ab, overnight at 4^0C with fresh blocking buffers. Secondary

anti rabbit IgG (1:2000) was used to detect the expression pattern of CC3. The membranes

were treated with ECL substrate (Bio-Rad) prior to observe the stained protein bands in

Azure Biosystem Chemi Doc system. Densitometric analysis was done using ImageJ and

Image Lab software (Bio-rad).

Cloning and expression of NS1 genes of Dengue virus type 1, 2, 3

RNA from virus was extracted using High Pure Viral Nucleic acid extraction kit (Roche).

Using gene specific reverse primers of target genes, cDNAs were synthesized using

Superscript-III (Invitrogen). Respective cDNA was used as template to PCR-amplify the

desired target. PCR products were confirmed by AGEP using 0.8-1% agarose and purified

using PCR purification kit (Qiagen). In case of NS1 gene, for all three serotypes, the gene

corresponding to signal sequences of 23-29 amino acids upstream of NS1 protein was

included for NS1 gene amplification for cloning purposes. Primers for cloning contained

appropriate restriction enzyme cutting sites, for instance, HindIII and BamHI restriction sites

in forward and reverse primers respectively in case of DV1 NS1 gene (plus signal sequence).

In case of DV2 NS1, NheI and XhoI restriction sites were incorporated in forward and

reverse primers respectively. For, DV3 NS1, forward primer contained NheI and reverse

primer contained BamHI restriction sites. Restriction enzymes digestion was carried out for

respective PCR products and expression vectors pcDNA3.1 (+). Ligation was done using T4

DNA ligase (Promega), followed by cloning in XL1-Blue cells. Plasmid was purified using

Purelink-Midi plasmid purification kit (Invitrogen). During expression, plasmid transfection

was done using Fugene HD (Promega), following manufacturer's instructions.

DNA sequences deposited in GenBank	Accession numbers
DV1-HNSB-P4 sequence for NS1 gene cloning	MT072226
DV2-HNSB-P4 sequence for NS1 gene cloning	MT072227
DV3-HNSB-P4 sequence for NS1 gene cloning	MT072228
Oligonucleotide primer sequences (5'-3')	**Name of primers**
CGG CTA GCA GCA TGG GRT TGA ATT CAA ARA AYA CWT CC	DV3NS1F
CGC GGA TCC TTA BGC TGA GRC TAA AGA CTT TAC C	DV3NS1R
CGC GCT AGC GCC ATG AAT TCA CGY AGC ACC TC	DV2NS1F
CGC CTC GAG TTA RGC TGT RAC CAA AGA ATT G	DV2NS1R
CGA AGC TTA GCA TGA GGA RCA CGT CMC TYT CGA TG	DV1NS1F
CGC GGA TCC TTA TGC AGA GAC CAT TGA CCT GAC	DV1NS1R

MTT assay

Huh7 cells were seeded as monolayer in 96 wells plate. Cells were infected with DV or

transfected with NS1 gene construct. One column of cells was left uninfected/un-transfected,

as positive control while another column was not seeded with cells but filled with media only,

as negative control. Media was removed 48h post infection/transfection, from each well and

the cells were washed using 1X PBS. Then 90 µl DMEM (Phenol red-free) and 10 µl MTT

solution were added to each well. The plate was incubated at 37^0C and 5% CO_2 for four hours

in a humidified CO_2 incubator for the formation of Formazan crystals in the living cells.

Media was discarded from all wells; 100 µl DMSO was added to each well and the contents

of the wells were mixed properly to dissolve the crystals. The plate was incubated for 30mins

and absorbance was measured at 590nm wavelength.

% viable cells= (OD of sample-OD of blank)/ (OD of control-OD of blank) x 100

Immunofluorescence experiments

For DAPI-staining, monolayer of Huh7 cells was cultured on 22mm cover slips and treated (DV infection or NS1 gene transfection) or left untreated as needed. 48h post treatment media was removed and cells were fixed with ice-cold 70% ethanol. This was followed by one wash with NF water (Ambion). Cover slips were then soaked using lint free paper and mounted with Prolong Diamond antifade mountant with DAPI (Invitrogen). Images were taken using EVOS FL cell imaging system.

In case of DV envelope immunofluorescence, monolayer of Huh7 cells was grown on six chambered slide (Genetix). DV1, DV2 or DV3 were inoculated at 10 virus copies/cell. Virus adsorption was done for 2h. At 96h post infection, media was removed and cells were washed twice with PBS. Cells were subsequently fixed using 4% PFA in PBS for 10min at RT. Cells were again washed twice with 1XPBS. Cells were permeabilized with 0.1% Triton X100 in 1XPBST for 15mins at RT. Then blocking was done with 1%BSA and 22.52mg/ml Glycine in PBST for 45mins at RT on rocker. Cells were incubated with diluted (1:40) primary Ab (Ab41349) in 1% BSA in PBST for one hour at RT on a rocking platform. The antibody solution was then removed by decanting and the cells were washed three times with PBST, each wash for 5mins. The cells were then incubated with diluted (1:500) secondary Ab (Ab150113) in 1% BSA in PBST for 30mins at RT. Secondary Ab was removed and cells were washed four times with PBST, each of five min duration, on rocking platform. The slides were allowed to get dry and mounted with Prolong Diamond antifade mountant with DAPI (Invitrogen). Images were taken using Fluoview 10i, Confocal microscope (Olympus).

Acknowledgements

We thank Mr. Tanmoy Dolui for his advice during TUNEL assay. Thanks to Mr. Subrata Roy for his suggestions in wet lab work. H.N. thanks Mr. Tathagata Kayal for his help during cell culture. H.N. acknowledges Council of Scientific and Industrial Research (CSIR) for SRF in pursuing this work. This work was supported by CSIR-IICB institutional funding. The authors acknowledge CSIR-IICB for providing laboratory facilities for conducting the current work.

References

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7.

2. WHO. Dengue: guidelines for diagnosis, treatment, prevention, and control [Internet]. World Health Organization. 2009. 160 p. Available from: www.who.int/tdr

3. Sambasivarao S V. Structure of Dengue Virus: Implications for Flavivirus Organization, Maturation, and Fusion. Cell. 2013;18(9):1199–216.

4. Chuansumrit A, Chaiyaratana W, Pongthanapisith V, Tangnararatchakit K, Lertwongrath S, Yoksan S. The use of dengue nonstructural protein 1 antigen for the early diagnosis during the febrile stage in patients with dengue infection. Pediatr Infect Dis J. 2008;27(1):43–8.

5. Youn S, Li T, McCune BT, Edeling MA, Fremont DH, Cristea IM, et al. Evidence for a Genetic and Physical Interaction between Nonstructural Proteins NS1 and NS4B That Modulates Replication of West Nile Virus. J Virol [Internet]. 2012;86(13):7360–71. Available from: http://jvi.asm.org/.

6. Lindenbach BD, Rice CM. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. J Virol [Internet]. 1999;73(6):4611–21. Available from: http://jvi.asm.org/

7. Avirutnan P, Fuchs A, Hauhart RE, Somnuke P, Youn S, Diamond MS, et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med [Internet]. 2010;207(4):793–806. Available from: www.jem.org/cgi/doi/10.1084/jem.20092545

8.   Young PR, Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, et al.

Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts

endothelial cell monolayer integrity Dengue virus NS1 protein activates cells via Toll-

like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med.

2015;7(304):1–10.

9.   Lin C-F, Lei H-Y, Shiau A-L, Liu H-S, Yeh T-M, Chen S-H, et al. Endothelial Cell

Apoptosis Induced by Antibodies Against Dengue Virus Nonstructural Protein 1 Via

Production of Nitric Oxide. J Immunol [Internet]. 2002 Jul 15 [cited 2019 Jul

28];169(2):657–64. Available from:

http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.169.2.657

10. Cheng H-J, Luo Y-H, Wan S-W, Lin C-F, Wang S-T, Thanh Hung N, et al.

Correlation between Serum Levels of Anti-Endothelial Cell Autoantigen and Anti-

Dengue Virus Nonstructural Protein 1 Antibodies in Dengue Patients. Am J Trop Med

Hyg. 2015;92(5):989–95.

11. Liao H, Xu J, Huang J. FasL/Fas pathway is involved in dengue virus induced

apoptosis of the vascular endothelial cells. J Med Virol [Internet]. 2010 Aug [cited

2019 Dec 4];82(8):1392–9. Available from: http://doi.wiley.com/10.1002/jmv.21815

12. Long X, Li Y, Qi Y, Xu J, Wang Z, Zhang X, et al. XAF1 contributes to dengue virus-

induced apoptosis in vascular endothelial cells. FASEB J [Internet]. 2013 Mar [cited

2019 Dec 4];27(3):1062–73. Available from: http://www.fasebj.org/doi/10.1096/fj.12-

213967

13. Chen H-C, Hofman FM, Kung JT, Lin Y-D, Wu-Hsieh BA. Both Virus and Tumor

Necrosis Factor Alpha Are Critical for Endothelium Damage in a Mouse Model of

Dengue Virus-Induced Hemorrhage. J Virol. 2007 Jun 1;81(11):5518–26.

14.   Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan

K, et al. Vascular Leakage in Severe Dengue Virus Infections: A Potential Role for the

Nonstructural Viral Protein NS1 and Complement. J Infect Dis. 2006 Apr

15;193(8):1078–88.

15.   Chen HR, Lai YC, Yeh TM. Dengue virus non-structural protein 1: A pathogenic

factor, therapeutic target, and vaccine candidate. Vol. 25, Journal of Biomedical

Science. BioMed Central Ltd.; 2018. p. 1–11.

16.   Thomas SJ. NS1: A corner piece in the dengue pathogenesis puzzle? Sci Transl Med

[Internet]. 2015 Sep 9 [cited 2020 Feb 29];7(304):304fs37. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/26355028

17.   Halstead SB. Pathogenesis of Dengue: Dawn of a New Era. Vol. 4, F1000Research.

Faculty of 1000 Ltd; 2015.

18.   Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E.

Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented

by NS1 vaccination. Sci Transl Med. 2015;7(304).

19.   Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, et al. High

Circulating Levels of the Dengue Virus Nonstructural Protein NS1 Early in Dengue

Illness Correlate with the Development of Dengue Hemorrhagic Fever. J Infect Dis.

2002;186(8):1165–8.

20.   Glasner DR, Puerta-Guardo H, Beatty PR, Harris E. The Good, the Bad, and the

Shocking: The Multiple Roles of Dengue Virus Nonstructural Protein 1 in Protection

and Pathogenesis.

21.   ten Bosch QA, Clapham HE, Lambrechts L, Duong V, Buchy P, Althouse BM, et al.

Contributions from the silent majority dominate dengue virus transmission. Ferguson

NM, editor. PLOS Pathog [Internet]. 2018 May 3 [cited 2020 Feb 15];14(5):e1006965.

Available from: http://dx.plos.org/10.1371/journal.ppat.1006965

22.   Ha TTN, Huy NT, Murao LA, Lan NTP, Thuy TT, Tuan HM, et al. Elevated levels of

cell-free circulating DNA in patients with acute dengue virus infection. PLoS One.

2011;6(10):1–7.

23.   Okamoto T, Suzuki T, Kusakabe S, Tokunaga M, Hirano J, Miyata Y, et al. Regulation

of apoptosis during flavivirus infection [Internet]. Vol. 9, Viruses. 2017. Available

from: www.mdpi.com/journal/viruses

24.   Lee C-J, Liao C-L, Lin Y-L. Flavivirus Activates Phosphatidylinositol 3-Kinase

Signaling To Block Caspase-Dependent Apoptotic Cell Death at the Early Stage of

Virus Infection. J Virol. 2005;79(13):8388–99.

25.   Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al.

Antibody-dependent enhancement of severe dengue disease in humans. Science (80-).

2017 Nov 17;358(6365):929–32.

26.   Nunes PCG, Nogueira RMR, Heringer M, Chouin-Carneiro T, Rodrigues CDDS, De

Filippis AMB, et al. NS1 antigenemia and viraemia load: Potential markers of

progression to dengue fatal outcome? Viruses. 2018 Jun 14;10(6).

27.   Dhanoa A, Hassan SS, Ngim CF, Lau CF, Chan TS, Adnan NAA, et al. Impact of

dengue virus (DENV) co-infection on clinical manifestations, disease severity and

laboratory parameters. BMC Infect Dis. 2016;16(1).

28.   Raut R, Corbett KS, Tennekoon RN, Premawansa S, Wijewickrama A, Premawansa

G, et al. Dengue type 1 viruses circulating in humans are highly infectious and poorly

neutralized by human antibodies. Proc Natl Acad Sci U S A [Internet]. 2019 Jan 2

[cited 2020 Feb 15];116(1):227–32. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/30518559

29.   Colpitts TM, Barthel S, Wang P, Fikrig E. Dengue virus capsid protein binds core

histones and inhibits nucleosome formation in human liver cells. PLoS One. 2011;6(9).

30.   Sangiambut S, Keelapang P, Aaskov J, Puttikhunt C, Kasinrerk W, Malasit P, et al.

Multiple regions in dengue virus capsid protein contribute to nuclear localization

during virus infection. J Gen Virol. 2008;89(5):1254–64.

31.   Kumar A, Buhler S, Selisko B, Davidson A, Mulder K, Canard B, et al. Nuclear

Localization of Dengue Virus Nonstructural Protein 5 Does Not Strictly Correlate with

Efficient Viral RNA Replication and Inhibition of Type I Interferon Signaling. J Virol.

2013 Apr 15;87(8):4545–57.

32.   Puerta-Guardo H, Glasner DR, Harris E. Dengue Virus NS1 Disrupts the Endothelial

Glycocalyx, Leading to Hyperpermeability. Kuhn RJ, editor. PLOS Pathog [Internet].

2016 Jul 14 [cited 2020 Jan 8];12(7):e1005738. Available from:

http://dx.plos.org/10.1371/journal.ppat.1005738

33.   Phuong NTN, Manh DH, Dumre SP, Mizukami S, Weiss LN, Van Thuong N, et al.

Plasma cell-free DNA: a potential biomarker for early prediction of severe dengue.

Ann Clin Microbiol Antimicrob [Internet]. 2019 Dec 13 [cited 2019 Dec 4];18(1):10.

Available from: https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-

019-0309-x

34.   Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam A V. Rapid detection and

typing of dengue viruses from clinical samples by using reverse transcriptase-

polymerase chain reaction. J Clin Microbiol. 1992;30(3):545–51.

Fig 1. Dengue virus and NS1 only, both can induce Cleaved Caspase3. (**a**) Western blots
data of Cleaved Caspase3 (CC3) expression in monolayer of Huh7 cells. Lane1: Untreated
cell Control replicate 1 (R1); Lane2: Untreated cell Control R2; Lane3: DV1 infected cells
(10 virus copies/cell) R1; Lane4: DV1 infected cells (10 virus copies/cell) R2; L5: 3.3μg
DV1-NS1-plasmid construct transfection; L6: 1.0 μg DV1-NS1 transfection R1; L7: 1.0 μg
DV1-NS1 transfection R2; L8: 0.5 μg DV1-NS1 transfection. (**b**) Densitometry of bands
from (a) for CC3. (**c**) Western blots data of CC3 expression in monolayer of Vero cells.
Lane1: Cells treated with Camptothecin (4μM) for 12h; Lane2: DV1 infected cells (10 virus
copies/cell); Lane3: DV2 infected cells (10 virus copies/cell) R1; Lane4: Cell Control. (**d**)
Densitometry of bands from (c) for CC3. Both graphs show the average quantification from
three independent experiments and error bars indicate SD.

Fig 2. Dengue virus shows control/check over apoptotic DNA break in DV infected cells.
(**a**) TUNEL assay representative data from monolayer of Huh7 cells, infected with DV1-
HNSB-P4 (10 virus copies/cell) or transfected with 1 μg or 3.3μg pcDNA3.1 (+)-DV1-NS1
construct/well of six well plate (as mentioned in figures). Cells were processed for TUNEL
assay after 96h post infection or transfection. (**b**) Histogram of percentage of differentially
treated cells that were found to be positive in TUNEL assay as in (**a**). (**c**) TUNEL assay data
from monolayer of Vero cells with DV1 infection (10virus copies/cell) and transfection with
3.3 μg pcDNA3.1 (+)-DV1-NS1 construct (as mentioned in figures). (**d**) Histogram of
percentage of differentially treated cells that were found to be positive in TUNEL assay as in
(**c**). (**e**) Representative result of TUNEL assay from monolayer of Huh7 cells infected with 10
virus copies (DV1, DV2 or DV3) /cell, and cells transfected with DV1-HNSB-P4-NS1, DV2-
HNSB-P4-NS1 or DV3-HNSB-P4-NS1 plasmid construct (3.3μg) in each well of six well
plate. (**f**) Histogram of TUNEL positive percentage of cells as in (**e**). All histograms show the
average quantification from three replicates per condition and error bars indicate SD.

Fig 3. Dengue virus exerts inhibitory effect over induced apoptotic DNA break and counterbalances NS1 mediated nuclear damage. (**a**) Gel Electrophoresis image, from left, Lane1 contains whole genomic DNA of Camptothecin (4μM) treated Vero cells; Lane2 contains DNA from Camptothecin (4μM) treated DV1-HNSB-P4 infected (10 virus copies/cell) Vero cells; Lane3 contains DNA of only DV1-HNSB-P4 infected cells; Lane 4 contains DNA from untreated cells. Equal amount of DNA was loaded in each well. Lane5 contains DNA ladder. (**b**) Relative densitometric analysis of lanes of gel image (**a**). (**c**) Monolayer of Huh7 cells, grown on 22mm coverslip were infected with DV1-HNSB-P4 (10 virus copies/cell). For transfection, 1.0 μg of plasmid containing the DV1-NS1 construct was used. 1.0 μg plasmid was chosen to keep the secreted sNS1 level similar to that in case of infected ones. In case of mock transfection, only Fugene was used without plasmid. Nuclei were stained with DAPI at 48h post infection or transfection. Images (40X) are representatives from multiple replicates from two different experiments. Scale bar, 100μm. Campt.-Camptothecin, DV1:DV1-HNSB-P4, C.Cntrl-Untreated Cell Control.

Fig 4. Immunofluorescence of viral envelope in DV1 or DV2 infected Huh7 cells.
Monolayer of Huh7 cells was infected with DV1-HNSB-P4 or DV2-HNSB-P4 (10 virus
copies/cell). At 96h post infection cells were fixed and treated with anti-DV envelope Ab and
Alexa fluor 488 tagged secondary Ab. Nuclei of cells were stained with DAPI. Images (60X)
are representative of multiple replicates from two different experiments. Scale bar, 20µm.

700 **Fig 5. Dengue virus counteracts apoptosis in virus infected cells even in the presence of**
701 **NS1 virotoxin that is alone capable of inducing apoptosis-schematic summary of the**
702 **evidences.**

704 **Supporting Information**

705 **Supplementary Table 1**

Experiment with relevant Figure number	Type of cells & type of culture plate	Sample identification	Infection of DENV/ Transfection of NS1	NS1 in Inoculum (µg)	Yield of NS1 (µg) excluding NS1 in inoculum	Fold change of NS1 (µg) over inoculum	Yield NS1 conc. (µg/ml)	Time of harvesting after infection or Transfection	Virus copies/ cell	Transfected plasmid (µg)	Mean yield (µg/ml)	SD
Fig:1(a) WB	Huh7, 6well	DV1-HNSB-P4(R1)	Infection of DV1-HNSB-P4	0.48	10.23	21.26	3.41	96hrs post infection	10	NA	**2.53**	**0.79**
	Huh7, 6well	DV1-HNSB-P4(R2)	Infection of DV1-HNSB-P4	0.48	8.71	18.10	2.90	96hrs post infection	10	NA		
	Huh7, 6well	DV1-HNSB-P4-NS1(R1)	Transfection of DV1-HNSB-P4-NS1	NA	8.9	NA	2.97	96hrs post transfection	NA	1	**2.55**	**0.59**
	Huh7, 6well	DV1-HNSB-P4-NS1(R2)	Transfection of DV1-HNSB-P4-NS1	NA	9.35	NA	3.12	96hrs post transfection	NA	1		
	Huh7, 6well	DV1-HNSB-P4-NS1(3.3)	Transfection of DV1-HNSB-P4-NS1	NA	14.22	NA	4.74	96hrs post transfection	NA	3.3	**4.36**	**0.33**
	Huh7, 6well	DV1-HNSB-P4-NS1(0.5)	Transfection of DV1-HNSB-P4-NS1	NA	0.96	NA	0.32	96hrs post transfection	NA	0.5	**0.36**	**0.04**
	Huh7, 6well	DV1-HNSB-P4-NS1(0.5)	Transfection of DV1-HNSB-P4-NS1	NA	1.2	NA	0.40	96hrs post transfection	NA	0.5		
	Huh7, 6well	DV1-HNSB-P4-NS1(0.5)	Transfection of DV1-HNSB-P4-NS1	NA	1.08	NA	0.36	96hrs post transfection	NA	0.5		
Fig2:(a) TUNEL	Huh7, 6well	DV1-HNSB-P4(R1)	Infection of DV1-HNSB-P4	0.2	6.57	32.25	2.19	96hrs post infection	10	NA	**2.53**	**0.79**
	Huh7, 6well	DV1-HNSB-P4(R2)	Infection of DV1-HNSB-P4	0.2	4.81	23.59	1.60	96hrs post infection	10	NA		
	Huh7, 6well	DV1-HNSB-P4-NS1(R1)	Transfection of DV1-HNSB-P4-NS1	NA	5.68	NA	1.89	96hrs post transfection	NA	1	**2.55**	**0.59**
	Huh7, 6well	DV1-HNSB-P4-NS1(R2)	Transfection of DV1-HNSB-P4-NS1	NA	6.65	NA	2.22	96hrs post transfection	NA	1		
	Huh7, 6well	DV1-HNSB-P4-NS1(3.3) (R1)	Transfection of DV1-HNSB-P4-NS1	NA	12.48	NA	4.16	96hrs post transfection	NA	3.3	**4.36**	**0.33**
	Huh7, 6well	DV1-HNSB-P4-NS1(3.3) (R2)	Transfection of DV1-HNSB-P4-NS1	NA	12.54	NA	4.18	96hrs post transfection	NA	3.3		
Fig2:(c) TUNEL	Vero, 6well	DV1-HNSB-P4(R1)	Infection of DV1-HNSB-P4	0.2	1.11	2.04	0.37	62 hrs post infection	10	NA	**0.40**	**0.09**
	Vero, 6well	DV1-HNSB-P4(R2)	Infection of DV1-HNSB-P4	0.2	0.98	2.04	0.33	62 hrs post infection	10	NA		
	Vero, 6well	DV1-HNSB-P4(R3)	Infection of DV1-HNSB-P4	0.2	1.5	2.04	0.50	62 hrs post infection	10	NA		
	Vero, 6well	DV1-HNSB-P4-NS1(R1)	Transfection of DV1-HNSB-P4-NS1	NA	2.7	NA	0.70	62hrs post Transfection	NA	3.3	**0.73**	**0.04**
	Vero, 6well	DV1-HNSB-P4-NS1(R2)	Transfection of DV1-HNSB-P4-NS1	NA	2.18	NA	0.73	62hrs post Transfection	NA	3.3		

	Vero, 6well	DV1-HNSB-P4-NS1(R3)	Transfection of DV1-HNSB-P4-NS1	NA	2.32	NA	0.77	62hrs post Transfection	NA	3.3		
Fig 2(e) TUNEL	Huh7, 6well	DV2-HNSB-P4(R1)	Infection of DV2-HNSB-P4	0.35	8.21	23.46	2.74	96hrs post infection	10	NA	**2.71**	**0.08**
	Huh7, 6well	DV2-HNSB-P4(R2)	Infection of DV2-HNSB-P4	0.35	8.33	23.80	2.78	96hrs post infection	10	NA		
	Huh7, 6well	DV2-HNSB-P4(R3)	Infection of DV2-HNSB-P4	0.35	7.88	22.51	2.63	96hrs post infection	10	NA		
	Huh7, 6well	DV2-HNSB-P4-NS1(3.3)(R1)	Transfection of DV2-HNSB-P4-NS1	NA	6.11	NA	2.04	96hrs post transfection	NA	3.3	**1.94**	**0.11**
	Huh7, 6well	DV2-HNSB-P4-NS1(3.3)(R2)	Transfection of DV2-HNSB-P4-NS1	NA	5.89	NA	1.96	96hrs post transfection	NA	3.3		
	Huh7, 6well	DV2-HNSB-P4-NS1(3.3)(R3)	Transfection of DV2-HNSB-P4-NS1	NA	5.44	NA	1.81	96hrs post transfection	NA	3.3		
	Huh7, 6well	DV3-HNSB-P4(R1)	Infection of DV3-HNSB-P4	0.23	3.85	16.74	1.28	96hrs post infection	10	NA	**1.21**	**0.15**
	Huh7, 6well	DV3-HNSB-P4(R2)	Infection of DV3-HNSB-P4	0.23	3.94	17.13	1.31	96hrs post infection	10	NA		
	Huh7, 6well	DV3-HNSB-P4(R3)	Infection of DV3-HNSB-P4	0.23	3.13	13.61	1.04	96hrs post infection	10	NA		
	Huh7, 6well	DV3-HNSB-P4-NS1(3.3)(R1)	Transfection of DV3-HNSB-P4-NS1	NA	5.2	NA	1.73	96hrs post transfection	NA	3.3	**1.56**	**0.16**
	Huh7, 6well	DV3-HNSB-P4-NS1(3.3)(R2)	Transfection of DV3-HNSB-P4-NS1	NA	4.58	NA	1.53	96hrs post transfection	NA	3.3		
	Huh7, 6well	DV3-HNSB-P4-NS1(3.3)(R3)	Transfection of DV3-HNSB-P4-NS1	NA	4.23	NA	1.41	96hrs post transfection	NA	3.3		
Fig:3(a) Ladder assay	Vero, T-25	DV1-HNSB-P4	Infection of DV1-HNSB-P4	0.49	2.64	5.39	0.53	62 hrs post infection	10	NA		
	Vero, T-25	DV1-HNSB-P4+Camp	Infection of DV1-HNSB-P4	0.49	2.72	5.55	0.54	62 hrs post infection	10	NA		
Fig:3(c) DAPI	Huh7, 6well	DV1-HNSB-P4(R1)	Infection of DV1-HNSB-P4	0.32	3.05	9.53	1.02	48hrs post infection	10	NA	**0.95**	**0.08**
	Huh7, 6well	DV1-HNSB-P4(R2)	Infection of DV1-HNSB-P4	0.32	2.6	8.13	0.87	48hrs post infection	10	NA		
	Huh7, 6well	DV1-HNSB-P4(R3)	Infection of DV1-HNSB-P4	0.32	2.89	9.03	0.96	48hrs post infection	10	NA		
	Huh7, 6well	DV1-HNSB-NS1(R1)	Transfection of DV1-HNSB-NS1	NA	3.51	NA	1.17	48hrs post transfection	NA	1	**1.15**	**0.03**
	Huh7, 6well	DV1-HNSB-NS1(R2)	Transfection of DV1-HNSB-NS1	NA	3.5	NA	1.17	48hrs post transfection	NA	1		
	Huh7, 6well	DV1-HNSB-NS1(R3)	Transfection of DV1-HNSB-NS1	NA	3.34	NA	1.11	48hrs post transfection	NA	1		